Prescient Therapeutics Ltd (ASX:PTX) CEO Steven Yatomi-Clarke tells Proactive the company has been granted additional Orphan Drug Designation for PTX-100 for the treatment of T-cell lymphomas (TCL), including cutaneous TCL (CTCL). The designation from the Office of Orphan Products Development at the US Food and Drug Administration, follows ODD for peripheral TCL (PTCL) in 2022. The latest designation broadens the clinical-stage oncology company’s range to all TCLs.
Prescient Therapeutics thrilled with additional Orphan Drug Designation status for PTX-100
